BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37103074)

  • 1. The Combination Sorafenib-raloxifene-loratadine as a Novel Potential Therapeutic Approach Against Human Liver Cancer.
    Villarruel-Melquiades F; Hernandez-Gallegos E; Solano-Agama C; Mendoza-Garrido ME; Camacho J
    In Vivo; 2023; 37(3):1156-1163. PubMed ID: 37103074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escin-sorafenib synergy up-regulates LC3-II and p62 to induce apoptosis in hepatocellular carcinoma cells.
    Hussain Y; Singh J; Meena A; Sinha RA; Luqman S
    Environ Toxicol; 2024 Feb; 39(2):840-856. PubMed ID: 37853854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
    Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
    J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy.
    Gnocchi D; Castellaneta F; Cesari G; Fiore G; Sabbà C; Mazzocca A
    J Pharm Pharmacol; 2021 Sep; 73(10):1369-1376. PubMed ID: 34014301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.
    Taha AM; Aboulwafa MM; Zedan H; Helmy OM
    Sci Rep; 2022 Oct; 12(1):17889. PubMed ID: 36284117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.
    Ebrahim HM; El-Rouby MN; Morsy ME; Said MM; Ezz MK
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3369-3376. PubMed ID: 31759361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Anti-Proliferative and Apoptotic Effects of Sorafenib Using miR-27a Inhibitor in Hepatocellular Carcinoma Cell Lines.
    Abdel Wahab AHA; Ayad EG; Abdulla MS; Sharada HM; Ashmawy AM
    Asian Pac J Cancer Prev; 2021 Sep; 22(9):2951-2958. PubMed ID: 34582667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
    Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR
    BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
    Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
    J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
    Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
    Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.
    Huang Y; Wang K; Gu C; Yu G; Zhao D; Mai W; Zhong Y; Liu S; Nie Y; Yang H
    Oncol Rep; 2018 Sep; 40(3):1525-1532. PubMed ID: 30015938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment.
    Cheng CC; Chao WT; Liao CC; Tseng YH; Lai YC; Lai YS; Hsu YH; Liu YH
    Cell Adh Migr; 2018 Jan; 12(1):19-27. PubMed ID: 28276928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
    Lai YL; Wang KH; Hsieh HP; Yen WC
    J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma.
    Samadaei M; Senfter D; Madlener S; Uranowska K; Hafner C; Trauner M; Rohr-Udilova N; Pinter M
    J Cell Biochem; 2022 Oct; 123(10):1663-1673. PubMed ID: 36271841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
    Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
    FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.
    Hsu CH; Weng PW; Chen MY; Yeh CT; Setiawan SA; Yadav VK; Wu ATH; Tzeng DTW; Gong JX; Yang Z; Tzeng YM
    Chem Biol Interact; 2023 Jan; 370():110329. PubMed ID: 36565974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.